CPIX vs. OMER, NKTR, ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.
Cumberland Pharmaceuticals vs. Its Competitors
Cumberland Pharmaceuticals (NASDAQ:CPIX) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.
In the previous week, Omeros had 10 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 18 mentions for Omeros and 8 mentions for Cumberland Pharmaceuticals. Omeros' average media sentiment score of 0.86 beat Cumberland Pharmaceuticals' score of 0.25 indicating that Omeros is being referred to more favorably in the news media.
15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 44.8% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Omeros has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -29.54%. Omeros' return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.
Omeros received 563 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 70.61% of users gave Omeros an outperform vote while only 41.81% of users gave Cumberland Pharmaceuticals an outperform vote.
Cumberland Pharmaceuticals has higher revenue and earnings than Omeros. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Omeros has a consensus price target of $18.00, indicating a potential upside of 397.24%. Given Omeros' stronger consensus rating and higher probable upside, analysts clearly believe Omeros is more favorable than Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.
Summary
Omeros beats Cumberland Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CPIX) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy CPIX Stock Free CPIX Stock Alerts